Sino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology. This collaboration brings together Sino Biological’s advanced protein expression and wet-lab capabilities with BioGeometry’s generative AI protein design and optimization platform. The two companies aim to enhance their joint offerings and explore high-value market opportunities globally.
Phoremost reports Series B extension
Latest NewsBritish protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes.
Funding for green insecticides
Latest NewsAgri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide.
Sino Biological and BioGeometry Deepen Strategic Cooperation to Empower Protein R&D with Generative AI
Sponsored PublicationsSino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology. This collaboration brings together Sino Biological’s advanced protein expression and wet-lab capabilities with BioGeometry’s generative AI protein design and optimization platform. The two companies aim to enhance their joint offerings and explore high-value market opportunities globally.
AZ’s lung cancer drug disappoints
Latest NewsA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: AstraZeneca’s share price dropped 5% following the announcement.
Epsilogen Ltd completes £12.5m Series B expansion
Latest NewsA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept for MOv18 IgE.
Swiss RNA maker Haya in huge licence deal
Latest NewsSwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Roche with good interim clinical results
Latest NewsRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis
Individor set to waive AEF0117 licence after Phase IIb failure
Latest NewsFollowing the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise its licence option until Aelis has submitted a final data analysis.
Nxera Pharma Ltd collects clinical US$35m milestone
Latest NewsNxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.
Anti-payload Antibodies: Facilitating ADC PK studies
Sponsored PublicationsAntibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.